A detailed history of Jfs Wealth Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Jfs Wealth Advisors, LLC holds 99 shares of VRTX stock, worth $44,586. This represents 0.0% of its overall portfolio holdings.

Number of Shares
99
Previous 97 2.06%
Holding current value
$44,586
Previous $45,000 2.22%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$460.0 - $505.78 $920 - $1,011
2 Added 2.06%
99 $46,000
Q2 2024

Jul 15, 2024

SELL
$392.81 - $485.53 $392 - $485
-1 Reduced 1.02%
97 $45,000
Q4 2023

Feb 07, 2024

BUY
$343.0 - $410.68 $3,430 - $4,106
10 Added 11.36%
98 $39,000
Q1 2023

Apr 19, 2023

SELL
$283.23 - $323.1 $2,832 - $3,231
-10 Reduced 10.2%
88 $27,000
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $3,143 - $3,536
-11 Reduced 10.09%
98 $28,000
Q3 2022

Oct 21, 2022

SELL
$273.83 - $305.53 $31,764 - $35,441
-116 Reduced 51.56%
109 $32,000
Q2 2022

Aug 02, 2022

BUY
$234.96 - $292.55 $21,146 - $26,329
90 Added 66.67%
225 $63,000
Q1 2022

May 02, 2022

BUY
$221.42 - $260.97 $2,214 - $2,609
10 Added 8.0%
135 $35,000
Q4 2021

Feb 03, 2022

SELL
$177.01 - $223.45 $82,486 - $104,127
-466 Reduced 78.85%
125 $27,000
Q3 2021

Nov 09, 2021

BUY
$181.39 - $202.99 $107,201 - $119,967
591 New
591 $107,000
Q1 2021

Apr 28, 2021

SELL
$207.02 - $241.31 $9,108 - $10,617
-44 Closed
0 $0
Q4 2020

Feb 01, 2021

BUY
$207.01 - $276.09 $9,108 - $12,147
44 New
44 $10,000
Q1 2020

Apr 29, 2020

SELL
$199.77 - $247.81 $799 - $991
-4 Closed
0 $0
Q3 2019

Oct 31, 2019

BUY
$166.23 - $187.09 $664 - $748
4 New
4 $1,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Jfs Wealth Advisors, LLC Portfolio

Follow Jfs Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jfs Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jfs Wealth Advisors, LLC with notifications on news.